General Information of Drug Transporter (DT)
DT ID	DTD0004 Transporter Info
Gene Name	ABCG2
Protein Name	Breast cancer resistance protein
Gene ID	9429
UniProt ID	Q9UNQ0
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs1061018
Site of GPD	chr4:88121701 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Allele G	Click to Show/Hide the Full List of Affected Drugs:            3 Drugs in Total
Nilotinib	Drug Info	Chronic myelogenous leukaemia	Correlated with the increased sensitivity of drug in K562 cells (compare with Allele A)		[ 1]
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the increased sensitivity of drug in K562 cells (compare with Allele A)		[ 1]
Dasatinib	Drug Info	Bacterial infections	Correlated with the increased sensitivity of drug in K562 cells (compare with Allele A)		[ 1]
Genetic Polymorphism	rs13120400
Site of GPD	chr4:88112375 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.1052/527 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:            2 Drugs in Total
Methotrexate	Drug Info	Psoriasis	Correlated with the increased drug response in patients (compare with genotypes tt + Ct)		[ 2]
Exjade	N.A.	Beta-Thalassemia	Correlated with the increased drug concentrations in patients (compare with Genotypes CT + TT)		[ 3], [ 4]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the increased drug response in patients (compare with Genotype TT)		[ 5]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Exjade	N.A.	Beta-Thalassemia	Correlated with the increased drug exposure in patients (compare with genotype CC)		[ 6]
Genetic Polymorphism	rs2231135
Site of GPD	chr4:88158842 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	G=0.0333/167 (Global)
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Methotrexate	Drug Info	Osteosarcoma	Correlated with the increased mucositis risk in patients (compare with genotype AA)		[ 7]
Genetic Polymorphism	rs2231137
Site of GPD	chr4:88139962 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.1575/789 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:            3 Drugs in Total
Nilotinib	Drug Info	Chronic myelogenous leukaemia	Correlated with the increased sensitivity to drug in K562 cells (compare with allele C)		[ 1]
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the increased sensitivity to drug in K562 cells (compare with allele C)		[ 1]
Dasatinib	Drug Info	Bacterial infections	Correlated with the increased sensitivity to drug in K562 cells (compare with allele C)		[ 1]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Irinotecan	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the increased diarrhea risk in patients (compare with genotype CC); Irrelevant to the neutropenia in patients (compare with genotype CC)		[ 8]
Genetic Polymorphism	rs2231142
Site of GPD	chr4:88131171 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>C / G>T
Minor Allele Frequency	T=0.1194/598 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:            3 Drugs in Total
Lamotrigine	Drug Info	Epilepsy	Irrelevant to the drug concentrations in patients (compare with Allele T); Irrelevant to the drug response in patients (compare with Allele T)		[ 9], [ 10]
Methotrexate	Drug Info	Rheumatoid Arthritis	Irrelevant to the drug discontinuation in patients (compare with Allele T)		[ 11]
Gemcitabine	Drug Info	Non-Small-Cell Lung Carcinoma	Irrelevant to the severity of neutropenia in patients (compare with Allele T)		[ 12]
Allele T	Click to Show/Hide the Full List of Affected Drugs:            8 Drugs in Total
Allopurinol	Drug Info	Gout	Correlated with the decreased drug response in patients (compare with allele G); Correlated with the increased drug dose in patients (compare with allele G)		[ 13], [ 14]
Rosuvastatin	Drug Info	Hypercholesterolemia	Correlated with the decreased LDL-C in patients (compare with allele G); Correlated with the increased drug plasma concentrations in patients (compare with allele G); Correlated with the increased drug response in patients (compare with allele G); Correlated with the increased reduction in low-density lipoprotein cholesterol (LDL-C) level in patients (compare with allele G)		[ 15], [ 16], [ 17], [ 18]
Lamotrigine	Drug Info	Epilepsy	Correlated with the increased drug concentrations in patients (compare with allele G)		[ 9]
Rosuvastatin	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with allele G)		[ 20]
Nilotinib	Drug Info	Chronic myelogenous leukaemia	Correlated with the increased sensitivity to drug in K562 cells (compare with allele G)		[ 1]
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the increased sensitivity to drug in K562 cells (compare with allele G)		[ 1]
Dasatinib	Drug Info	Bacterial infections	Correlated with the increased sensitivity to drug in K562 cells (compare with allele G)		[ 1]
Gefitinib	Drug Info	Lung Neoplasm	Irrelevant to the increased drug toxicity risk in patients (compare with allele G)		[ 22]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:            8 Drugs in Total
Leucovorin	Drug Info	Colorectal Neoplasm	Correlated with the decreased drug response in patients (compare with Genotypes GT + TT)		[ 21]
Fluorouracil	Drug Info	Colorectal Neoplasm	Correlated with the decreased drug response in patients (compare with Genotypes GT + TT); Irrelevant to the drug response in patients (compare with Genotypes GT + TT)		[ 21], [ 22]
Oxaliplatin	Drug Info	Colorectal Neoplasm	Correlated with the decreased drug response in patients (compare with Genotypes GT + TT); Irrelevant to the drug response in patients (compare with Genotypes GT + TT)		[ 21], [ 22]
Rosuvastatin	Drug Info	Hypercholesterolemia	Correlated with the decreased percentage change in LDL-cholesterol levels in patients (compare with Genotype TT)		[ 23]
Rosuvastatin	Drug Info	Healthy Individuals	Correlated with the decreased the total area under the plasma concentration-time curve (AUC) of drug in healthy individuals (compare with genotypes tt + Gt)		[ 24]
Irinotecan	Drug Info	Colorectal Neoplasm	Irrelevant to the drug response in patients (compare with Genotypes GT + TT)		[ 22]
Gefitinib	Drug Info	Non-Small-Cell Lung Carcinoma	Irrelevant to the drug toxicity risk in patients (compare with Genotypes GT + TT); Irrelevant to the increased likelihood of drug toxicity in patients (compare with Genotypes GT + TT)		[ 25], [ 26]
Capecitabine	Drug Info	Colorectal Neoplasm	Correlated with the decreased drug response in patients (compare with Genotypes GT + TT)		[ 21]
Genotype GT	Click to Show/Hide the Full List of Affected Drugs:            7 Drugs in Total
Imatinib	Drug Info	Neoplasm	Correlated with the decreased drug metabolism in patients (compare with genotype GG)		[ 27]
Fluorouracil	Drug Info	Breast Neoplasm	Correlated with the increased anemia risk in patients (compare with genotype GG)		[ 28]
Doxorubicin	Drug Info	Breast Neoplasm	Correlated with the increased anemia risk in patients (compare with genotype GG)		[ 28]
Cyclophosphamide	Drug Info	Breast Neoplasm	Correlated with the increased anemia risk in patients (compare with genotype GG)		[ 28]
Sulfasalazine	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with genotype GG)		[ 29]
Rosuvastatin	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with genotype GG)		[ 29]
Gefitinib	Drug Info	Lung Neoplasm	Correlated with the increased likelihood of diarrhea in patients (compare with genotype GG)		[ 30]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:          12 Drugs in Total
Sulfasalazine	Drug Info	Healthy Individuals	Correlated with the decreased drug clearance in healthy individuals (compare with genotypes GG + Gt)		[ 31], [ 32]
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the decreased likelihood of adverse events in patients (compare with genotype GG)		[ 33]
Sunitinib	Drug Info	Renal Cell Carcinoma	Correlated with the decreased neutropenia risk in patients (compare with genotypes GG + Gt); Correlated with the increased drug toxicity risk in patients (compare with genotypes GG + Gt); Correlated with the increased hand-foot syndrome risk in patients (compare with genotypes GG + Gt); Correlated with the increased neutropenia risk in patients (compare with genotypes GG + Gt); Correlated with the increased thrombocytopenia risk in patients (compare with genotypes GG + Gt); Irrelevant to the anemia risk in patients (compare with genotypes GG + Gt)		[ 34], [ 35]
Apixaban	Drug Info	Atrial Fibrillation	Correlated with the increased drug concentrations in patients (compare with genotype GG)		[ 36]
Lamotrigine	Drug Info	Epilepsy	Correlated with the increased drug concentrations in patients (compare with genotypes GG + Gt)		[ 10]
Dolutegravir	Drug Info	HIV Infection	Correlated with the increased drug concentrations in patients (compare with genotypes GG + Gt)		[ 38]
Fluvastatin	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with genotypes GG + Gt)		[ 39]
Simvastatin	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with genotypes GG + Gt)		[ 39]
Rosuvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased drug plasma concentrations in patients (compare with genotype GG)		[ 23]
Rosuvastatin	Drug Info	Healthy Individuals	Correlated with the increased the total area under the plasma concentration-time curve (AUC) in healthy individuals (compare with genotypes GG + Gt)		[ 41]
Atorvastatin	Drug Info	Healthy Individuals	Correlated with the increased the total area under the plasma concentration-time curve (AUC) of drug in healthy individuals (compare with genotypes GG + Gt)		[ 41]
Opioids	N.A.	Neoplasm	Correlated with the increased drug response (compare with genotypes GG + Gt)		[ 42]
Genotypes GG + GT	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Apixaban	Drug Info	Atrial Fibrillation	Correlated with the increased drug clearance in patients (compare with Genotype TT)		[ 41]
Genotypes GT + TT	Click to Show/Hide the Full List of Affected Drugs:            7 Drugs in Total
Allopurinol	Drug Info	Gout	Correlated with the decreased drug response in patients (compare with genotype GG)		[ 42]
Lamotrigine	Drug Info	Epilepsy	Correlated with the increased drug concentrations in patients (compare with genotype GG)		[ 43]
Tenofovir	Drug Info	HIV Infection	Correlated with the increased drug concentrations in patients (compare with genotype GG)		[ 44]
Sunitinib	Drug Info	Neoplasm	Correlated with the increased drug exposure in patients (compare with genotype GG)		[ 45]
Sulfasalazine	Drug Info	Rheumatoid Arthritis	Correlated with the increased drug response in patients (compare with genotype GG)		[ 46]
Gemcitabine	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the increased progression-free survival in patients (compare with genotype GG); Correlated with the increased severity of thrombocytopenia in patients (compare with genotype GG); Irrelevant to the overall survival in patients (compare with genotype GG)		[ 12]
Efavirenz	Drug Info	HIV Infection	Correlated with the increased abnormal dreams risk in patients (compare with genotype GG)		[ 48]
Genetic Polymorphism	rs41282401
Site of GPD	chr4:88115014 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G
Minor Allele Frequency	G=0.0002/1 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:            3 Drugs in Total
Nilotinib	Drug Info	Chronic myelogenous leukaemia	Correlated with the increased sensitivity to drug in K562 cells (compare with Allele G)		[ 1]
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the increased sensitivity to drug in K562 cells (compare with Allele G)		[ 1]
Dasatinib	Drug Info	Bacterial infections	Correlated with the increased sensitivity to drug in K562 cells (compare with Allele G)		[ 1]
Genetic Polymorphism	rs45605536
Site of GPD	chr4:88097518 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.0018/9 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:            2 Drugs in Total
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the increased sensitivity to drug in K562 cells (compare with allele C)		[ 1]
Dasatinib	Drug Info	Bacterial infections	Correlated with the increased sensitivity to drug in K562 cells (compare with allele C)		[ 1]
Genetic Polymorphism	rs58818712
Site of GPD	chr4:88097526 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C
Allele C	Click to Show/Hide the Full List of Affected Drugs:            3 Drugs in Total
Nilotinib	Drug Info	Chronic myelogenous leukaemia	Correlated with the increased sensitivity to drug in K562 cells (compare with Allele A)		[ 1]
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the increased sensitivity to drug in K562 cells (compare with Allele A)		[ 1]
Dasatinib	Drug Info	Bacterial infections	Correlated with the increased sensitivity to drug in K562 cells (compare with Allele A)		[ 1]
Genetic Polymorphism	rs7699188
Site of GPD	chr4:88174909 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	A=0.2460/1232 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:            3 Drugs in Total
Irinotecan	Drug Info	Colorectal Neoplasm	Correlated with the increased grade 3-4 nonhematological toxicity risk in patients (compare with allele G); Correlated with the increased tumor response rate in patients (compare with allele G)		[ 48]
Fluorouracil	Drug Info	Colorectal Neoplasm	Correlated with the increased grade 3-4 nonhematological toxicity risk in patients (compare with allele G); Correlated with the increased tumor response rate in patients (compare with allele G)		[ 48]
Leucovorin	Drug Info	Colorectal Neoplasm	Correlated with the increased grade 3-4 nonhematological toxicity risk in patients (compare with allele G); Correlated with the increased tumor response rate in patients (compare with allele G)		[ 48]
Genetic Polymorphism	rs12505410
Site of GPD	chr4:88109689 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C / T>G
Minor Allele Frequency	G=0.2794/1399 (Global)
Genotypes GG + GT	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the increased drug response in patients (compare with Genotype TT)		[ 5]
Genetic Polymorphism	rs17731538
Site of GPD	chr4:88134227 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.0960/481 (Global)
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Methotrexate	Drug Info	Psoriasis	Correlated with the increased drug response in patients (compare with allele AG)		[ 2]
Genetic Polymorphism	rs2199939
Site of GPD	chr8:40053975 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.0946/474 (Global)
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Rosuvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased drug response (compare with genotype CC)		[ 49]
Genetic Polymorphism	rs2725252
Site of GPD	chr4:88140758 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	A=0.4145/2076 (Global)
Genotypes AC + CC	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the increased drug response in patients (compare with genotype AA)		[ 5]
Genetic Polymorphism	rs3114020
Site of GPD	chr4:88162514 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.4249/2128 (Global)
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Lamotrigine	Drug Info	Epilepsy	Correlated with the increased drug concentrations in patients (compare with Genotype TT)		[ 43]
Genetic Polymorphism	rs4148157
Site of GPD	chr4:88099782 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.1006/504 (Global)
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:            1 Drugs in Total
Topotecan	Drug Info	Brain Neoplasm	Correlated with the increased drug concentrations in patients (compare with genotype GG)		[ 50]
References
1	Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line. Pharmacogenet Genomics. 2014 Jan;24(1):52-61.
2	Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol. 2008 Aug;128(8):1925-9.
3	Role of pharmacogenetics on deferasirox AUC and efficacy. Pharmacogenomics. 2016 Apr;17(6):561-72.
4	Deferasirox AUC efficacy cutoff and role of pharmacogenetics. Eur J Clin Pharmacol. 2016 Sep;72(9):1155-7.
5	High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients. Oncotarget. 2013 Oct;4(10):1582-91.
6	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics. 2017 Apr;18(6):539-554.
7	Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate. Pharmacogenomics J. 2015 Oct;15(5):385-90.
8	Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer. 2009 Jan;63(1):115-20.
9	Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy. Br J Clin Pharmacol. 2018 Sep;84(9):2106-2119.
10	Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy. Epilepsy Res. 2016 Nov;127:186-190.
11	Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis. Pharmacogenomics J. 2017 Oct;17(5):412-418.
12	Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy. BMC Cancer. 2018 May 11;18(1):555.
13	Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. Clin Pharmacol Ther. 2015 May;97(5):518-25.
14	The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool. Br J Clin Pharmacol. 2018 May;84(5):937-943.
15	Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet. 2013 Aug;6(4):400-8.
16	Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenet Genomics. 2010 Oct;20(10):634-7.
17	Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circ Cardiovasc Genet. 2010 Jun;3(3):276-85.
18	ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010 May;87(5):558-62.
19	Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol. 2015 Mar;71(3):329-40.
20	Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer. Cancer Chemother Pharmacol. 2010 Sep;66(4):691-8.
21	Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer. Med Oncol. 2014 Jan;31(1):802.
22	Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol. 2010 Jul 10;28(20):3227-33.
23	Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics. 2013 Aug;14(11):1283-94.
24	Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta. 2006 Nov;373(1-2):99-103.
25	Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2015 Jul;16(4):274-81.
26	Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics. 2011 Feb;12(2):159-70.
27	Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res. 2008 Nov 1;14(21):7102-9.
28	Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget. 2018 Jan 10;9(10):9114-9136.
29	Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. J Pharm Sci. 2017 Sep;106(9):2688-2694.
30	Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
31	Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene. Br J Clin Pharmacol. 2015 Nov;80(5):1236-7.
32	Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacol Ther. 2008 Jul;84(1):95-103.
33	Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenet Genomics. 2010 Jun;20(6):367-76.
34	Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Cancer Chemother Pharmacol. 2013 Oct;72(4):825-35.
35	Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma. PLoS One. 2015 Aug 5;10(8):e0134102.
36	Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation. Pharmacogenet Genomics. 2017 Sep;27(9):329-336.
37	High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants. Pharmacogenet Genomics. 2017 Nov;27(11):416-419.
38	Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics. 2009 Oct;10(10):1617-24.
39	ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2009 Aug;86(2):197-203.
40	Clinical and pharmacogenetics associated with recovery time from general anesthesia. Pharmacogenomics. 2018 Sep 1;19(14):1111-1123.
41	Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. Br J Clin Pharmacol. 2018 Jun;84(6):1301-1312.
42	ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenomics J. 2017 Mar;17(2):201-203.
43	Polymorphisms of ABCG2, ABCB1 and HNF4 are associated with Lamotrigine trough concentrations in epilepsy patients. Drug Metab Pharmacokinet. 2015 Aug;30(4):282-7.
44	Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV. Pharmacogenomics J. 2018 Apr;18(2):245-250.
45	Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. Invest New Drugs. 2015 Feb;33(1):257-68.
46	Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis. Pharmacogenomics J. 2014 Aug;14(4):350-5.
47	Impact of pharmacogenetics on CNS side effects related to efavirenz. Pharmacogenomics. 2013 Jul;14(10):1167-78.
48	Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. Pharmacogenet Genomics. 2013 Oct;23(10):549-57.
49	Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet. 2012 Apr 1;5(2):257-64.
50	Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. Drug Metab Dispos. 2016 Jul;44(7):1116-22.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.